摘要
目的探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗联合化疗对晚期胃癌核因子相关因子-2(Nrf2)、抗氧化反应元件(ARE)蛋白表达水平的影响,评价其治疗效果。方法回顾性选取晚期胃癌患者接受DC-CIK免疫治疗联合常规化疗120例作为联合组,常规化疗晚期胃癌患者60例作为对照组,选取时间2014年3月至2016年3月。统计两组治疗后的疗效和不良反应发生情况,检测治疗前后细胞免疫和体液免疫的变化,并检测血清中Nrf2、ARE蛋白的表达水平。结果联合组骨髓抑制发生率明显低于对照组(P<0.05);联合组患者治疗后免疫细胞比率显著高于对照组患者(P<0.05);联合组治疗后IgG、IgM、IgA均明显高于治疗前及对照组(P<0.05);联合组Nrf2、ARE含量高于对照组(P<0.05)。联合组患者客观有效率与对照组比较,差异无统计学意义(P>0.05)。结论DC-CIK免疫治疗联合化疗能改善晚期胃癌患者的免疫功能,提高患者Nrf2、ARE蛋白表达水平,不良反应较少。
Objective To discuss the effect of DC-CIK immunotherapy combined with chemotherapy on the expression of Nrf2 and ARE protein in advanced gastric cancer and to discuss its clinical therapeutic effect. Methods 120 cases of advanced gastric cancer received DC-CIK immunotherapy combined with conventional chemotherapy in our hospital（ combined group）. 60 cases of advanced gastric cancer treated by conventional chemotherapy were selected as control group from March 2014 - 2016 March. After treatment,the occurrence of adverse reactions and the changes of cellular and humoral immunity before and after treatment were analyzed. The expression level of Nrf2 and ARE protein in serum were detected. Results The incidence of myelosuppression in the combined group was significantly lower than that in the control group（ P〈0. 05）.The proportion of immune cells in the combined group was significantly higher than that in the control group（ P〈0. 05）. The IgG,IgM and IgA of the combined group were significantly higher than those before the treatment and the control group（ P〈0. 05）,and the content of Nrf2 and ARE in the combined group were higher than those of the control group（ P〈0. 05）. The objective and effective rate of the patients in the observation group were compared with that of the control group,and the difference was not statistically significant（ P〈0. 05）. Conclusion DC-CIK immunotherapy chemotherapy can improve the immune function of patients with advanced gastric cancer,improve the expression level of Nrf2 and ARE,and have fewer side effects.
作者
杜敏
李志民
霍伟
DU Min;LI Zhi-min;HUO Wei(Department of Medical Oncology,Dalian Municipal Central Hospital,Dalian Liaoning 116033,China.)
出处
《临床和实验医学杂志》
2018年第15期1627-1630,共4页
Journal of Clinical and Experimental Medicine
